Abstract: The invention relates to a method of operating a four stroke internal combustion engine system (1), the engine system (1) comprising:—a four stroke internal combustion engine (2) provided with an intake duct (5),—a turbo compressor (6?) arranged to compress intake flow in the intake duct (5), and—a displacement machine (7) provided in the intake duct (5) downstream the turbo compressor (6?), wherein the displacement machine (7) is arranged to displace intake flow from an inlet to an outlet thereof. The method comprises the step of: operating the displacement machine (7) in a first mode where a pressure ratio (PR) given by a pressure at the outlet of the displacement machine (7) divided by a pressure at the inlet of the displacement machine (7) is substantially equal to 1. The invention also relates to a four stroke internal combustion engine system arranged to be operated by the above method.

Abstract: The invention provides novel 6-aryl or 6-heteroaryl 4-morpholin-4-yl-pyhdine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and R4 are as defined in the specification.

Abstract: The invention provides novel azaindolylpyridone and diazaindolylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory diseases, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R2, R3 and X are as defined in the specification.

Abstract: A conduit connection assembly includes a first conduit component having a first mating structure and a second conduit component having a second mating structure adapted to be mated with the first mating structure. A sealing arrangement is provided for sealing between the mating structures. The sealing arrangement includes at least two spaced sealing members defining an intermediate space and the assembly includes a pressure relief opening arranged in communication with the intermediate space between the two spaced sealing members.

Abstract: The invention provides novel pyridinamine-pyridone and pyrimidinamine-pyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections; (I) wherein R1, R2, R3 and Z are as defined in the specification.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.

Abstract: The invention provides novel pyridylpyridone compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, type II diabetes, inflammatory disease, autoimmune diseases, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and X are as defined in the specification.

Abstract: A conduit connection assembly includes a first conduit component having a first mating structure and a second conduit component having a second mating structure adapted to be mated with the first mating structure. A sealing arrangement is provided for sealing between the mating structures. The sealing arrangement includes at least two spaced sealing members defining an intermediate space and the assembly includes a pressure relief opening arranged in communication with the intermediate space between the two spaced sealing members.

Abstract: A conduit connection assembly includes a first conduit part and a second conduit part, assembled to form a conduit connection delimiting a first fluid conducting volume from a second fluid conducting volume. The first and second fluid conducting volumes communicate with each other via a pressure change inducing device. During use of the conduit connection assembly, the pressure in the first conducting volume is higher than the pressure in the second conducting volume. A cavity is formed between the first and second conduit parts at a distance from the first fluid conducting volume, and a draining connection is adapted to provide a communication between the cavity and the second fluid conducting volume. A slot, formed by the assembly of the two conduit parts, provides a communication between the first fluid conducting volume and the cavity.

Abstract: A conduit connection assembly including a first conduit part and a second conduit part, adapted to be assembled to form a conduit connection delimiting a first fluid conducting volume, wherein the conduit connection assembly presents a second fluid conducting volume, the first and second fluid conducting volumes being arranged to communicate with each other via a pressure change inducing device so as to form a common fluid guide, whereby during use of the conduit connection assembly the pressure in the first conducting volume is higher than the pressure in the second conducting volume, in that a cavity is formed between the first and second conduit parts at a distance from the first conducting volume, and a draining connection is adapted to provide a communication between the cavity and the second fluid conducting volume.

Abstract: Beta-secretase inhibitors, of formula (I) as described in the specification, pharmaceutical compositions comprising them and therapeutic methods using them for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

Abstract: Beta-secretase inhibitors, of formula (I) as described in the specification, pharmaceutical compositions comprising them and therapeutic methods using them for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's Disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.